Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Disorders of Leukocytes01:27

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Lineage Commitment01:21

Lineage Commitment

Commitment is the  process whereby stem cells:
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inflammatory immune modulators of AML lung infiltration and respiratory failure.

Nature immunology·2026
Same author

Sunburned blasts: ultraviolet imprints on aneuploid pediatric leukemia.

Haematologica·2026
Same author

Cell autonomous inflammation in VEXAS is mediated by cGAS-STING.

bioRxiv : the preprint server for biology·2026
Same author

RAS pathway activation and microenvironmental adaptation as hallmarks of myeloid sarcoma.

Blood cancer discovery·2026
Same author

3D Chromosome Remodeling in B-cell Development and Acute Lymphoblastic Leukemia.

Blood cancer discovery·2026
Same author

Epigenetic reactivation of the tumor suppressor ZBTB7A by KDM4 inhibition in human acute myeloid leukemia.

Science translational medicine·2026

Related Experiment Video

Updated: May 9, 2026

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia
06:33

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Published on: November 10, 2023

A new player SETs in myeloid malignancy.

Thomas Trimarchi, Panagiotis Ntziachristos, Iannis Aifantis

    Nature Genetics
    |July 30, 2013
    PubMed
    Summary
    This summary is machine-generated.

    Recurrent mutations in the SETBP1 gene are found in myeloid leukemias. Further research is needed to understand how these SET-binding protein 1 mutations cause disease.

    More Related Videos

    Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
    09:01

    Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

    Published on: March 26, 2018

    Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
    06:39

    Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

    Published on: October 3, 2018

    Related Experiment Videos

    Last Updated: May 9, 2026

    Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia
    06:33

    Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

    Published on: November 10, 2023

    Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
    09:01

    Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

    Published on: March 26, 2018

    Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
    06:39

    Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

    Published on: October 3, 2018

    Area of Science:

    • Genetics
    • Oncology
    • Molecular Biology

    Background:

    • Recurrent mutations in SETBP1, encoding SET-binding protein 1, are increasingly identified in myeloid malignancies.
    • These mutations are observed in conditions such as chronic myeloid leukemia and acute myeloid leukemia.

    Discussion:

    • The identified SETBP1 mutations frequently occur within the SKI-homologous domain.
    • The precise pathogenic mechanisms driving leukemogenesis due to these mutations are not yet fully elucidated.

    Key Insights:

    • SETBP1 mutations represent a significant genetic factor in myeloid leukemias.
    • Understanding the functional impact of mutations in the SKI-homologous domain is crucial.

    Outlook:

    • Further investigation into the molecular pathways affected by SETBP1 mutations is warranted.
    • This research may reveal novel therapeutic targets for myeloid malignancies.